Načítá se...
In silico driven redesign of a clinically relevant antibody for the treatment of GD2 positive tumors.
Ganglioside GD2 is a cell surface glycolipid that is highly expressed on cancer cells of neuroectodermal origin, including neuroblastoma, retinoblastoma, melanoma, sarcomas, brain tumors and small cell lung cancer. Monoclonal antibodies (MoAb) that target GD2 have shown clinical efficacy in the trea...
Uloženo v:
| Hlavní autoři: | , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Public Library of Science (PLoS)
2013-01-01
|
| Edice: | PLoS ONE |
| On-line přístup: | http://europepmc.org/articles/PMC3656052?pdf=render |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|